Cargando…
Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells
Introduction: Recent studies have shown that miRNA-10b is highly expressed in high-grade glioblastoma multiforme (GBM), and its inhibition leads to deregulation of multiple pathways in tumorigenesis, resulting in repression of tumor growth and increased apoptosis. Thus, we hypothesized that suppress...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311069/ https://www.ncbi.nlm.nih.gov/pubmed/37398551 http://dx.doi.org/10.3389/fmolb.2023.1179343 |
_version_ | 1785066667057872896 |
---|---|
author | Chen, Ming Kim, Bryan Robertson, Neil Mondal, Sujan Kumar Medarova, Zdravka Moore, Anna |
author_facet | Chen, Ming Kim, Bryan Robertson, Neil Mondal, Sujan Kumar Medarova, Zdravka Moore, Anna |
author_sort | Chen, Ming |
collection | PubMed |
description | Introduction: Recent studies have shown that miRNA-10b is highly expressed in high-grade glioblastoma multiforme (GBM), and its inhibition leads to deregulation of multiple pathways in tumorigenesis, resulting in repression of tumor growth and increased apoptosis. Thus, we hypothesized that suppressing miR-10b could enhance the cytotoxicity of conventional GBM chemotherapy with temozolomide (TMZ). Methods: Inhibition of miR-10b in glioblastoma cells was achieved using an experimental therapeutic consisting of anti-miR10b antagomirs conjugated to iron oxide nanoparticles (termed MN-anti-miR10b). The nanoparticles serve as delivery vehicles for the antagomirs as well as imaging reporters guiding the delivery in future animal studies. Results: Treatment of U251 and LN229 human glioblastoma cells with MN-anti-miR10b led to inhibition of miR-10b accompanied by repression of growth and increase in apoptosis. We next explored whether MN-anti-miR10b could enhance the cytotoxic effect of TMZ. During these studies, we unexpectedly found that TMZ monotherapy increased miR-10b expression and changed the expression of corresponding miR-10b targets. This discovery led to the design of a sequence-dependent combination treatment, in which miR-10b inhibition and induction of apoptosis by MN-anti-miR10b was followed by a sub-therapeutic dose of TMZ, which caused cell cycle arrest and ultimately cell death. This combination was highly successful in significant enhancement of apoptosis and decrease in cell migration and invasiveness. Discussion: Considering the unexpected effects of TMZ on miR-10b expression and possible implications on its clinical application, we reasoned that comprehensive in vitro studies were warranted before embarking on studies in animals. These intriguing findings serve as a solid foundation for future in vivo studies and offer promise for the successful treatment of GBM. |
format | Online Article Text |
id | pubmed-10311069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103110692023-07-01 Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells Chen, Ming Kim, Bryan Robertson, Neil Mondal, Sujan Kumar Medarova, Zdravka Moore, Anna Front Mol Biosci Molecular Biosciences Introduction: Recent studies have shown that miRNA-10b is highly expressed in high-grade glioblastoma multiforme (GBM), and its inhibition leads to deregulation of multiple pathways in tumorigenesis, resulting in repression of tumor growth and increased apoptosis. Thus, we hypothesized that suppressing miR-10b could enhance the cytotoxicity of conventional GBM chemotherapy with temozolomide (TMZ). Methods: Inhibition of miR-10b in glioblastoma cells was achieved using an experimental therapeutic consisting of anti-miR10b antagomirs conjugated to iron oxide nanoparticles (termed MN-anti-miR10b). The nanoparticles serve as delivery vehicles for the antagomirs as well as imaging reporters guiding the delivery in future animal studies. Results: Treatment of U251 and LN229 human glioblastoma cells with MN-anti-miR10b led to inhibition of miR-10b accompanied by repression of growth and increase in apoptosis. We next explored whether MN-anti-miR10b could enhance the cytotoxic effect of TMZ. During these studies, we unexpectedly found that TMZ monotherapy increased miR-10b expression and changed the expression of corresponding miR-10b targets. This discovery led to the design of a sequence-dependent combination treatment, in which miR-10b inhibition and induction of apoptosis by MN-anti-miR10b was followed by a sub-therapeutic dose of TMZ, which caused cell cycle arrest and ultimately cell death. This combination was highly successful in significant enhancement of apoptosis and decrease in cell migration and invasiveness. Discussion: Considering the unexpected effects of TMZ on miR-10b expression and possible implications on its clinical application, we reasoned that comprehensive in vitro studies were warranted before embarking on studies in animals. These intriguing findings serve as a solid foundation for future in vivo studies and offer promise for the successful treatment of GBM. Frontiers Media S.A. 2023-06-15 /pmc/articles/PMC10311069/ /pubmed/37398551 http://dx.doi.org/10.3389/fmolb.2023.1179343 Text en Copyright © 2023 Chen, Kim, Robertson, Mondal, Medarova and Moore. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Chen, Ming Kim, Bryan Robertson, Neil Mondal, Sujan Kumar Medarova, Zdravka Moore, Anna Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells |
title | Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells |
title_full | Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells |
title_fullStr | Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells |
title_full_unstemmed | Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells |
title_short | Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells |
title_sort | co-administration of temozolomide (tmz) and the experimental therapeutic targeting mir-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311069/ https://www.ncbi.nlm.nih.gov/pubmed/37398551 http://dx.doi.org/10.3389/fmolb.2023.1179343 |
work_keys_str_mv | AT chenming coadministrationoftemozolomidetmzandtheexperimentaltherapeutictargetingmir10bprofoundlyaffectsthetumorigenicphenotypeofhumanglioblastomacells AT kimbryan coadministrationoftemozolomidetmzandtheexperimentaltherapeutictargetingmir10bprofoundlyaffectsthetumorigenicphenotypeofhumanglioblastomacells AT robertsonneil coadministrationoftemozolomidetmzandtheexperimentaltherapeutictargetingmir10bprofoundlyaffectsthetumorigenicphenotypeofhumanglioblastomacells AT mondalsujankumar coadministrationoftemozolomidetmzandtheexperimentaltherapeutictargetingmir10bprofoundlyaffectsthetumorigenicphenotypeofhumanglioblastomacells AT medarovazdravka coadministrationoftemozolomidetmzandtheexperimentaltherapeutictargetingmir10bprofoundlyaffectsthetumorigenicphenotypeofhumanglioblastomacells AT mooreanna coadministrationoftemozolomidetmzandtheexperimentaltherapeutictargetingmir10bprofoundlyaffectsthetumorigenicphenotypeofhumanglioblastomacells |